The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo-controlled trial of colchicine following acute myocardial infarction

Thomas Hennessy

Research output: ThesisMaster's Thesis

491 Downloads (Pure)

Abstract

This Thesis is based on the LoDoCo-MI trial: A pilot RCT of colchicine following acute myocardial infarction. I explore inflammation as a key pathological process in atherosclerosis/acute coronary syndrome and all attempts to date to treat the same as well as future trials in this setting. Following MI, patients with the persistently elevated biomarker high-sensitivity Creactive protein (hs-CRP), are at increased risk of recurrent cardiovascular events. Colchicine is an anti-inflammatory drug used in LoDoCo-MI to reduce residual inflammation in an attempt to decrease recurrent CV events. Before colchicine can be routinely used in ACS, extensive feasibility, tolerability, safety data is needed.
Original languageEnglish
QualificationMasters
Awarding Institution
  • The University of Western Australia
Supervisors/Advisors
  • Hillis, Graham, Supervisor
  • Schultz, Carl, Supervisor
Thesis sponsors
Award date10 Aug 2021
DOIs
Publication statusUnpublished - 2021

Fingerprint

Dive into the research topics of 'The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo-controlled trial of colchicine following acute myocardial infarction'. Together they form a unique fingerprint.

Cite this